Tysabri Continues Comeback; On Pace To Reach 100,000 Patients In 2010
This article was originally published in The Pink Sheet Daily
Executive Summary
The once-withdrawn MS drug continues to gain patients in the U.S. and EU, with an improving safety profile, Biogen says.